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Abstract 
Background. Polyomavirus-associated nephropathy (PVAN) is one of the most common viral 
disease affecting renal allograft, with BK being the most frequent causal agent and  JCV being 
considered responsible in <3% of the cases.  
Objectives. To quantify polyomaviruses BK and JC load by real-time TaqMan PCR in tissue 
specimens (renal and ureteral) from kidney transplant recipients.   
Study design and Methods. One-hundred-thirty-eight specimens (125 kidneys, 13 ureters) 
obtained from 109 patients were evaluated by quantitative real-time PCR for the detection of 
BKV- and JCV-DNA. Demographic, virological, and histopathological data were collected. 
Results. BKV-DNA was positive in 32 of 109 patients (29.6%) and JCV-DNA in 20 of 109 
patients (18.3%). The highest BK viral loads (>104  genome equivalents/cell) were found in 
two renal samples with histopathologically confirmed PVAN; while JC viral load was > 104 
genome equivalents/cell in one ureteral sample.  
Conclusions. Although quantitation of viral DNA on renal allograft biopsies could be 
complementary to histopathological evaluation and the highest viral load are detectable in 
renal specimens with PVAN, the identification of a diagnostic cut-off should require further 
studies. 
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Introduction 
BKV and JCV are members of the Polyomaviridae family with a genome homology of 
approximately 72%. Human polyomaviruses BK and JC are ubiquitous and following primary 
infection remain latent in the renourinary tract and B cells. Asymptomatic viruria may occur in 
both immunocompetent subjects and immunocompromised patients, while in transplanted 
kidney viral replication may determine polyomavirus-associated nephropathy (PVAN)  in 1-
10% of the patients, leading to graft failure in 30 up to 80% of the cases (Hirsch et al., 2005; 
Hirsch et al., 2006). Today, PVAN is one of the most common viral disease affecting renal 
allografts, with BKV being the most frequent causal agent and JCV being responsible in less 
than 3% of the cases (Kazory et al., 2003; Wen et al., 2004; Cavallo et al., 2007). However, in 
a recent study (Drachenberg et al., 2007) a biopsy-proven PVAN was diagnosed in six renal 
transplant recipients with exclusive JCV viruria out of 75 patients (8%) with BKV and/or JCV 
viruria, with an overall incidence during the study period of 0.9%. The definitive diagnosis of 
PVAN is made on the basis of histopathology, although this presents some drawbacks, 
including being invasive and limited sensitivity due to (multi)focal involvement. We present 
here results of quantitation of polyomaviruses BK and JC by Real-time TaqMan PCR in renal 
and ureteral specimens from renal transplant recipients.   
 Material and Methods 
All 109 renal transplant recipients who underwent at least one graft biopsy for clinical and/or 
laboratory suspicion of rejection, PVAN, or other causes, in a 18-month period were 
evaluated. In 13 patients ureteral specimens, obtained during pyelostomy performed for 
ureteral stenosis, were studied (for three of these patients a renal sample was also available). 
Overall, 138 clinical samples were evaluated. Relevant clinical and laboratory data were 
abstracted from clinical charts and kidney transplant database. Informed consent was 
obtained from all the patients. BK viral load on concomitant serum and urine samples were 
available for 55 patients. Extraction from serum and urine samples was performed as 
previously described (Bergallo et al., 2006). Tissue specimens were formalin-fixed and 
paraffin-embedded; for DNA extraction, two-to-four sections (thickness, 4 µ) were incubated 
with 400 μL of lysis buffer (400 mM Tris-HCl 400 pH 7.5; 500 mM NaCl; 50 mM EDTA; 1% 
SDS) by vortexing for 30 sec, boiled for 10 min, vortexed for 30 sec, boiled for 10 min and 
vortexed again for 30 sec, then centrifuged for 1 min at 13.000 rpm at room temperature. 
Three hundred μL of the supernatant were mixed with 750 μL of absolute ethanol and 30 μL of 
3 M sodium acetate pH 5. After centrifugation for 5 min at 13.000 rpm at room temperature, 
the pellet was washed with 70% ethanol, air-dried for at least 30 min, resuspended in 50 μL of 
double-distilled H2O, and stored at -20°C prior to use.  
Tissue samples were tested for BKV- and JCV-DNA by Real-time quantitative TaqMan PCRs 
targeting viral genes encoding for the large T-antigens of each virus with the 7300 Real Time 
PCR System (Applied Biosystems, Monza, Italy). For BKV-DNA a commercial kit was used 
(Q-BKV, Nanogen Advanced Diagnostics, Milano, Italy), following the manufacturer’s 
instruction, while JCV-DNA was tested as previously described (McNees et al., 2005). Details  
are reported in Table 1. Amplifications were set up in a reaction volume of 25 μL, including 5 
μL of extracted sample or plasmid dilutions. No template control (sterile double-distilled H2O) 
was included in each PCR run. Standard curves for BKV- and JCV-DNA quantification were 
constructed by plotting the threshold cycle (Ct) against the logarithm of serial 10-fold dilutions 
(ranging from 102 to 105) of pBKV provided with the Real-Time kit and a plasmid containing 
full-lenght JCV-DNA (courtesy of T. Musso), respectively. The plasmid DNA concentration was 
determined by measuring the optical density at 260 nm. The DNA content in micrograms was 
converted to genomic copies using Avogadro’s number (6.023 x 1023) and the number of 
nucleotide pairs in the plasmid, and the average molecular weight of a nucleotide pair was 
assumed to be 660 µg. All measurements were performed in duplicate. To correct for the 
variable amount of DNA in different tissue samples, each sample was subjected to 
simultaneous TaqMan PCR for the housekeeping gene Glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH, Accession No. J04038), targeting the region between exon 6 and 8; 
primers and probe were designed using the Primer Express software (version 3.0, Applied 
Biosystems;Table 1). Results were considered acceptable only in the presence of GAPDH-
positivity. Standard curves for the GAPDH gene quantitation were constructed by plotting the 
Ct against the logarithm of serial dilutions of DNA extracted from peripheral blood leukocytes. 
The Ct values and number of BKV-DNA copies, JCV-DNA copies, and diploid sets of GAPDH-
gene were calculated from the standard curve. The assay was linear in the range 102-105 
copies per reaction. In case of results above the linear range serial 10-fold dilutions of 
extracted samples were made and quantification was obtained considering the mean of the 
results within the linear range. A “nucleotide-nucleotide blast” search for short nucleotide 
sequences performed at the National Center for Biotechnology Information and the National 
Library of Medicine web site confirmed that the primer pairs used for JCV amplify only 92 
clinical isolates of JCV and should not amplify other viruses pathogenic to humans. 
Amplification data were analyzed by the Sequence Detection System software (Applied 
Biosystems). 
For histopathologic evaluation periodic acid-Schiff, Masson’s trichrome, phosphotungstic acid 
hemotoxylin, and acid fucsin-orange G stains were performed. In case of suspected PVAN, 
immunohistochemistry (IHC) with immunoperoxidase staining was performed on fixed material 
using polyclonal anti-SV40 antibody (dilution 1:20,000; Lee Biomolecular Research Labs. San 
Diego CA), cross-reacting with BKV and JCV.  
Statistical analysis was performed using the chi square test with a commercially available 
software (MedCalc; version 9.2.1.0). A p value <0.05 was considered significant.  
 
Results 
Results are summarized in Table 2. Real-time PCR for BKV-DNA was positive in 37/138 
transplant biopsies (26.8%) from 32/109 patients (29.6%): 30/124 (24.2%) renal and 7/14 
(50%) ureteral samples, from 26/96 (27.9%) and 6/13 (46.2%) patients, respectively (for two 
patients BKV-positivity was concordant on renal and ureteral specimens). The positivity rate 
did not significantly differ between renal and ureteral samples. Concordant negative and 
positive results were found in all the cases, thus the highest load was considered in each 
patient. Median BKV viral load was 125 Geq/104 cells (range 40-1023067263; 25th percentile 
40, 75th percentile 361); tissue viral load was >75th percentile in ten  samples and >90th 
percentile (i.e. 66668.8) in five: 137126 in a renal specimen with post-transplantation 
glomerulopathy, 36448 and 601057 in two ureteral samples from a patient in whom renal 
specimen resulted negative to BKV and JCV, 493047821 and 1023067263 in two patients with 
PVAN. Viral load was 2058 Geq/104 cells in a renal specimen from a patient in which PVAN 
was subsequently diagnosed (pre-PVAN). JCV-DNA was positive in 24/138 biopsies (17.4%) 
from 20/109 patients (18.3%): 21/124 (16.9%) renal and 3/14 (21.4%) ureteral specimens, 
from 17/96 (17.7%) and 3/13 (23.1%) patients, respectively, without differences between renal 
and ureteral specimens. Median JCV viral load was 40 Geq/104 cells (range 36-23060245; 
25th percentile 40, 75th percentile 265); tissue viral load was >75th percentile in 7 specimens 
and >90th percentile (i.e. 1336) in three specimens: 1470 in a renal specimen with post-
transplantation glomerulopathy, 2002 and 23060245 in two ureteral samples. 
BKV and JCV were detected alone in 23 and 11 patients, respectively; both BKV-DNA and 
JCV-DNA were detectable in nine patients.  
Demographic, virological, and histopathological data are summarized in Table 3.  
 
Discussion 
The presence of latent BKV in renal tissue from kidney allograft recipients is well documented, 
ranging from 2.6% (Schmid et al., 2005) up to 16.2% (Randhawa et al., 2005). In our study 
BKV was detected in 26.8% of tissue specimens: 24.2% of renal biopsies and 50.0% of 
ureteral samples. Although our data are higher than those previously reported, the possibility 
of plasmid contamination was ruled out as the control plasmids were not produced in our 
laboratory; moreover, plasmid contamination during sample processing would affect a large 
number of samples. Polyomaviruses are normally latent in the urothelium, thus DNA-positivity 
could be simply indicating latency, as well as we cannot exclude contamination from urinary 
shedding or that virus might be derived from a reservoir present in infiltrating B-cells or other 
inflammatory cell population. The detection of BK viral load >90th percentile on two ureteral 
specimens in the absence of positivity on renal biopsy of the same patient obtained two 
months later suggest a role for BK in the development of ureteral stenosis and a localized 
ureteral reactivation, this also taking into account the negativity of viremia. JCV-DNA has been 
demonstrated in up to 10% of autoptic kidneys (Randhawa et al., 2005) and in 17.4% of both 
renal and ureteral specimens from our patients; however, no case of JCV-PVAN was 
diagnosed, while a value of 2.3 x 107 Geq/104 cells was detected on a ureteral specimen from 
a case which had been already reported (Cavallo et al., 2007).     
The histological diagnosis of PVAN can be challenging. While in intermediate/advanced 
stages florid cytopathic changes and inflammatory infiltrates represent the most typical 
patterns, in early stages viral inclusions may be absent, as well as inflammation may be 
scarce (Schmid et al., 2005). Considering this and the focal nature of renal involvement, 
polyomavirus-DNA quantitation could be useful in the presence of little evidence of viral 
cytopathy (Schmid et al., 2005). In a study by Randhawa and coll., a mean BKV load of 
7738.9 DNA copies/cell was found in renal allograft biopsies with active PVAN, while it was 
185.8 and 28.8 in pre-PVAN renal biopsies and in specimens from patients with asymptomatic 
BKV viruria, respectively (Randhawa et al., 2005). In our study BKV load in allograft biopsies 
with histologically confirmed PVAN was >104 Geq/cell, while ranged between 0.3 and 13.7 in 
patient with asymptomatic BK viruria (data not shown) and was <1 Geq/cell in the patient with 
pre-PVAN. Although, like most studies investigating BKVAN, our study was limited by the low 
number of affected patients, data obtained from our group and those by Randhawa and coll. 
indicate that the highest BKV load (in both the studies >103 copies/cell) are found in renal 
specimens from patients with active PVAN. The evidence that renal tubules accumulate 
thousands of viral particles before undergoing cell lysis underlines the role of cytopathic effect 
in renal allograft injury in PVAN (Randhawa et al., 2002). Considering pre-PVAN, giving the 
evaluation of only one case, our study failed to evidence a higher viral load in comparison to 
patients with asymptomatic viruria; alternatively this could be due to to the sampling interval, 
as specimen was evaluated 2.1 months before the diagnosis of PVAN was made. 
Because of focal involvement of PVAN, especially during the early stage of infection, 
sensistivity of histopathology and tissue PCR could be limited. Moreover, this could affect the 
degree of viral load; it has been suggested that BKV load is better measured in urine than in 
tissue, because urine represents material from the entire kidney (Randhawa et al., 2005). 
However, as some glomeruli are physiologically shut off, it seems possible that the affected 
inflamed tubuli may be underrepresented in the urine flow, but overrepresented in the blood.  
In conclusion, although quantitation of tissue viral DNA could be complementary to 
histopathological evaluation and the highest viral load are detectable in renal specimens with 
PVAN, i.e. >103 copies/cell, the identification of a diagnostic cut-off should require further 
studies, also taking into account the potential sampling errors and the evaluation of surrogate 
markers of viral replication (Hirsch et al., 2005).  
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Table 1. Technical details on Real Time PCR assays employed in this study. GAPDH, 
glyceraldehydes-3-phopshate dehydrogenase. 
 BKV JCV (modified from McNees et al., 2005)  GAPDH  
Primers  
Q-BKV Real Time 
PCR kit (Nanogen 
Adv. Diagnostics) 
F 5’-TTCTTCATGGCAAAACAGGTCTT-3’  
R  5’- GAATGGGAATCCTGGTGGAA -3’ 
F 5’-GCCAAAAGGGTCATCATCTC-3’ 
R 5’-GGGGCCATCCACAGTCTTCT-3’ 
Probe 
 
FAM-5’-CCACTTCTCATTAAATG-3’-MGB 
 
VIC-5’-TGGTATCGTGGAAGGA-3’-MGB 
Cycling conditions 50°C 2 min 
94°C 10 min 
95°C 15 sec 
60°C 1 min 
 
45 cycles 
Table 2. Results of polyomaviruses BK- and  JC-DNA detection in renal and 
ureteral specimens from renal transplant recipients. Pts, patients; R, renal 
samples; U, ureteral samples; SD, standard deviation. *Patients with histologically 
confirmed PVAN. 
 
Total  
Samples  
N =138  
Pts  
N = 109 
Samples 
N (%) 
 
Pts 
N (%) 
Viral load 
(Geq/10
4
 cells) 
  
BKV-DNA 37 (26.8%) 
 
 
- 30/124 (24.2%) R 
- 7/14 (50.0%) U 
32 (29.6%) 
 
 
- 26/96 (27.9%) R 
- 6/13 (46.2%) U 
Median 125 (range 40-1023067263;  
25
th
 percentile 40; 75
th
 percentile 361) 
*Two PVAN, 4.93 x 10
8
 and 1.02 x 10
9
   
Median 40, mean±SD 4907.0±25494.4 
Median 1059, mean±SD 106626±242646.4 
 
 
 
 
 
JCV-DNA 24 (17.4%) 20 (18.3%) Median 40 (range 36-23060245;  
25
th
 percentile 40; 75
th
 percentile 265) 
  
 - 21/124 (16.9%) R 
- 3/14 (21.4%) U 
- 17/96 (17.7%) R 
- 3/13 (23.1%) U 
Median 40, mean±SD 216.4±401.2 
Median 1020, mean±SD 1020.0±1385.9 
  
 
  
 
 
Table 3. Main features of renal transplant recipients and relation to polyomaviruses 
positivity. 
 
Patients 
Total N = 109 
BKV-DNA JCV-DNA 
POS. NEG. POS. NEG. 
M/F 66/43 15/17 51/26 11/9 55/34 
Age groups 
- <40 yrs (11) 
- 41-60 yrs (64) 
- >60 yrs (34) 
 
3 
16 
10 
 
8 
48 
24 
 
- 
20 
- 
 
11 
44 
34 
PVAN (2) 2 - - - 
Ureteral stenosis (13) 6* 7 3* 10 
Acute rejection (4) 2** 2 1** 3 
Post-transplantation 
glomerulopathy (6) 
 
4*** 
 
2 
 
3 
 
3 
 
*Viral load, JCV 2.3 x 107 Geq/104 cells in 1 patient and <104 in the remainings 
**Viral load <104 Geq/104 cells 
***Viral load, <105 Geq/104 cells  
